A Multicenter, Open-Label, Phase 1 First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous MNK-010 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
Price : $35 *
At a glance
- Drugs MNK 010 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Mallinckrodt Inc.
- 23 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2016.
- 23 May 2016 Status changed from recruiting to discontinued.
- 29 Jan 2014 New trial record